**Title of the proposal**

|  |  |
| --- | --- |
| **Principal Investigator 1 (Lead)****Title First Name Last Name**InstitutionInstitute/DepartmentStreetPost Code Zurich EmailCCCZ Member: Yes/No | **Principal Investigator 2 (for application of translational scientists)****Title First Name Last Name**InstitutionInstitute/DepartmentStreetPost Code Zurich EmailCCCZ Member: Yes/No |
| **Fellow (if known at the time of application)****Title First Name Last Name**InstitutionInstitute/DepartmentStreetPost Code Zurich Email |  |
|  |

|  |  |
| --- | --- |
| Please state whether a proposal for this project has been submitted to another funding body | Yes/No*If yes, please state funding body and funding amount* |
| Please state whether this project (or parts of it) are currently funded by another funding body | Yes/No*If yes, please state funding body and funding amount* |

**Keywords – Keyword, Keyword, Keyword**

*Please state 3-5 keywords for the project*

**1. Summary**

*Max. 400 words. The proposed research must aim to:**(****1****)**Encompass* ***innovative translation*** *of scientific findings into clinical practice. (****2****) Combine innovative clinical oncology, research and technologies to* ***develop novel diagnostic and therapeutic concepts towards precision oncology.***

Text

**2. Research plan**

**2.1. CURRENT STATE OF RESEARCH AND PRELIMINARY WORK**

*Max. 0.5 pages*

Text

**2.2. Aims**

*Please state max. 5 specific aims of your project.*

**Aim 1:**

**Aim 2:**

**Aim 3:**

**Aim ….**

**2.3. research plan**

*Please state specific tasks**(e.g. Task 1.1., Task 1.2., Task 2.1. etc.) and involved PIs matching your aims. Max. 2 pages.*

**Aim 1 – Task 1.1.: Title of Task,** *Involved PIs/Groups*

Rationale:

Hypothesis:

Methods:

Pitfalls and alternatives:

**Aim 2 - Task 2.1.: Title of Task,** *Involved PIs/Groups*

Rationale:

Hypothesis:

Methods:

Pitfalls and alternatives:

**Aim 3 - Task 3.1.: Title of Task,** *Involved PIs/Groups*

Rationale:

Hypothesis:

Methods:

Pitfalls and alternatives:

**2.4. Time schedule and milestones**

|  |  |  |
| --- | --- | --- |
| **Aim/Task(s)** | **2025 (Q1-4)**  | **2026 (Q1-4)** |
| Task 1.1: |  |  |
| Task 2.1: |  |  |
| Task 3.1: |  |  |
|  |  |  |

*Please indicate the scheduling of the tasks with “x”.*

**2.5. Budget Plan**

*Please delete not applicable row.*

|  |  |  |  |  |
| --- | --- | --- | --- | --- |
| **CCCZ Fellow Program (Call 2024)** | **CHF** | **CHF** | **CHF** | **CHF** |
|  | **2024** | **2025** | **2026** | **Totals** |
| CCCZ Clinician Scientist  |   | 55'000.00 |   | **55'000.00** |
| CCCZ Translational Scientist  |   | 115'000.00 | 115'000.00 | **230'000.00** |

**3. Mentoring and Career Development for CCCZ Fellow**

*0.3 Pages max. Please describe how the fellow will be supported to become independent researchers (advancement of research goals, skills and experience).*

Text

**4. Motivation Statement CCCZ Fellow**

*If fellow is already known at the time of application. Max. 0.3 pages. Describe your research interests and how the fellowship fits with your professional objectives.*

Text

**7. References**

*Max. 10 publications. Please cite only publications relevant for the project. Please underline the names of the applying PIs. Use the following format:*

Zingg D, Arenas-Ramirez N, Sahin D, Rosalia RA, Antunes AT, Haeusel J, Sommer L, and Boyman O. The epigenetic repressor Ezh2 controls adaptive resistance mechanisms to tumor immunotherapy. **Cell Reports** 2017;20:854-867. DOI: [10.1016/j.celrep.2017.07.007](https://doi.org/10.1016/j.celrep.2017.07.007)